Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6115861 | 0.80 | AHR (0.45) | SMN1; SMN2LMNAHPGDTSHRCYP1A2 | |
| SCHEMBL6115028 | 0.76 | CMA1 (1.00) | CMA1LMNAHPGDTSHRCYP1A2 | |
| SCHEMBL18900851 | 0.76 | CMA1 (0.72) | CMA1SMN1; SMN2LMNAHPGDTSHR | |
| SCHEMBL7963507 | 0.74 | CMA1 (0.73) | CMA1SMN1; SMN2LMNAHPGDTSHR | |
| SCHEMBL6115916 | 0.74 | CMA1 (0.81) | CMA1SMN1; SMN2P2RX3LMNAHPGD | |
| SCHEMBL30451982 | 0.73 | KDM4E (0.50) | SMN1; SMN2LMNATSHRL3MBTL1 | |
| SCHEMBL7962647 | 0.73 | CMA1 (0.78) | CMA1SMN1; SMN2P2RX3LMNAHPGD | |
| SCHEMBL7960570 | 0.72 | CMA1 (1.00) | CMA1SMN1; SMN2P2RX3TSHR | |
| SCHEMBL1852376 | 0.72 | CMA1 (0.60) | CMA1SMN1; SMN2P2RX3LMNAHPGD | |
| SCHEMBL1849731 | 0.71 | CMA1 (0.79) | CMA1SMN1; SMN2P2RX3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129863-A1 | CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885SMN1; SMN2 1912/4885P2RX3 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.